Boyer M - Search Results

1

What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.

Cooper WA, O'toole S, Boyer M, Horvath L, Mahar A. Cooper WA, et al. Among authors: boyer m. Pathology. 2011 Feb;43(2):103-15. doi: 10.1097/PAT.0b013e328342629d. Pathology. 2011. PMID: 21233671 Review.

2

Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.

Clarke SJ, Boyer MJ. Clarke SJ, et al. Among authors: boyer mj. Med J Aust. 1997 Jun 2;166(S1):S14-6. Med J Aust. 1997. PMID: 9201199

3

Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer.

Boyer MJ, Zalcberg J, Olver IN, Millward MJ, Richardson G, McKeage MJ. Boyer MJ, et al. Ann Oncol. 1997 May;8(5):485-9. doi: 10.1023/a:1008291606695. Ann Oncol. 1997. PMID: 9233529 Free article. Clinical Trial.

4

New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience.

Boyer MJ. Boyer MJ. Chest. 1998 Jan;113(1 Suppl):24S-27S. doi: 10.1378/chest.113.1_supplement.24s. Chest. 1998. PMID: 9438686 Review.

5

Non-surgical therapy for patients with advanced non-small cell lung cancer.

Clarke SJ, Boyer MJ. Clarke SJ, et al. Among authors: boyer mj. Respirology. 1998 Sep;3(3):175-82. doi: 10.1111/j.1440-1843.1998.tb00117.x. Respirology. 1998. PMID: 9767616 Review.

6

Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours.

Horvath LG, McCaughan BC, Stockle M, Boyer MJ. Horvath LG, et al. Among authors: boyer mj. Intern Med J. 2002 Mar;32(3):79-83. Intern Med J. 2002. PMID: 11885847

7

Smoking reduction does work: resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years.

Joshua AM, Boyer MJ, Subramanian R, Clarke SJ. Joshua AM, et al. Among authors: boyer mj. Respirology. 2005 Mar;10(2):233-8. doi: 10.1111/j.1440-1843.2005.00672.x. Respirology. 2005. PMID: 15823191

8

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials.

Vardy J, Dadasovich R, Beale P, Boyer M, Clarke SJ. Vardy J, et al. Among authors: boyer m. BMC Cancer. 2009 Apr 29;9:130. doi: 10.1186/1471-2407-9-130. BMC Cancer. 2009. PMID: 19402889 Free PMC article.

9

Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.

Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, Sutherland RL, Henshall SM, Horvath LG. Zhao L, et al. Among authors: boyer mj. Cancer Res. 2009 Oct 1;69(19):7696-703. doi: 10.1158/0008-5472.CAN-08-4901. Epub 2009 Sep 22. Cancer Res. 2009. PMID: 19773444

10

Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.

Boyer M, Horwood K, Pavlakis N, De Souza P, Millward M, Stein B, Johnston M, Abell F, Rischin D. Boyer M, et al. Asia Pac J Clin Oncol. 2012 Sep;8(3):248-54. doi: 10.1111/j.1743-7563.2012.01540.x. Epub 2012 May 15. Asia Pac J Clin Oncol. 2012. PMID: 22898114 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

928 results

Search Page

Filters